Summary
Most statements are about pricing/cost estimation and billing workflows, which are not addressed in the provided FDA prescribing information excerpts. The few clinical/product-related statements that are checkable (e.g., dosing regimen, route, weight-independent fixed dose) are not directly evidenced by the provided excerpts with enough precision to verify all details.
Category Scores
Accurate Statements
Tezspire is administered as an injection.
Supported in the provided labeling excerpt title: 'TEZSPIRE (tezepelumab-ekko) injection' and dosing section indicating subcutaneous administration.
Tezspire is given in a fixed dose per weight-independent regimen.
Supported by 'The recommended dosage ... is 210 mg administered subcutaneously once every 4 weeks.' (no weight-based dosing shown in provided excerpt).
Annual totals for Tezspire generally depend on how many injections occur per year under the prescribed schedule rather than dose changes for weight.
Consistent with fixed dose schedule in provided excerpt: 210 mg once every 4 weeks.
Unsupported Statements
Tezspire annual pricing is not consistent year to year or person to person.
No pricing, reimbursement, or cost variability content is present in the provided prescribing information excerpts.
The total annual cost of Tezspire depends on the dose and whether insurance coverage, rebates, or patient assistance apply.
Prescribing information excerpts provided do not address pricing drivers, rebates, or patient assistance.
Tezspire is typically billed per treatment cycle.
No billing/coding/cycle billing language is present in provided prescribing information excerpts.
For many patients, calculating the year depends on the labeled dosing schedule.
Label excerpt provides dosing frequency but does not discuss 'calculating annual cost' or that it depends on schedule.
The final out-of-pocket cost for Tezspire can vary widely by plan.
No out-of-pocket cost discussion in provided prescribing information excerpts.
Annual totals for Tezspire generally depend on how many injections occur per year under the prescribed schedule rather than dose changes for weight.
While dosing is fixed in label excerpt, the statement is framed as an annual-cost calculation claim; the label excerpt does not address cost calculations.
If you know the prescribed injection frequency and strength, annual treatment totals can be calculated and then combined with the insurer’s allowed amount and copay/coinsurance terms.
Label excerpt does not provide any guidance on insurers' allowed amounts, copay/coinsurance, or cost calculation workflows.
Patients’ annual spending on Tezspire usually falls into three categories: uninsured/self-pay, commercial insurance, and assistance programs.
Not addressed in provided prescribing information excerpts.
Uninsured/self-pay annual spending is closer to wholesale acquisition cost or cash price and can be very high.
No wholesale acquisition cost/cash price or uninsured cost information in provided excerpts.
With commercial insurance, annual out-of-pocket cost depends on the plan’s specialty drug rules, deductible status, and copays/coinsurance.
Not addressed in provided prescribing information excerpts.
Assistance programs can significantly reduce what eligible patients pay through copay support or other manufacturer/coverage pathways.
No manufacturer assistance/copoly programs content in provided prescribing information excerpts.
Tezspire dosing frequency (e.g., every 4 weeks or every 8 weeks) can be used to estimate annual cost.
The provided label excerpt states once every 4 weeks; 'every 8 weeks' is not supported by provided dosing excerpt.
A practical workflow to estimate Tezspire annual cost includes identifying treatment frequency, finding the billed price per dose or insurer allowed amount, multiplying by the number of doses per year, and applying plan cost-sharing and deductible remaining.
No billing/insurer-allowed amount/deductible/cost-sharing workflow is present in provided prescribing information excerpts.
Tezspire dosing frequency (e.g., every 4 weeks or every 8 weeks) can be used to estimate annual cost.
Contains dosing-frequency claim 'every 8 weeks' not supported by the provided prescribing information excerpt.
Contradictions
Low
AI Statement
Tezspire dosing frequency (e.g., every 4 weeks or every 8 weeks) can be used to estimate annual cost.
Label Reference
Dosage and Administration (2.1) excerpt: 'The recommended dosage of TEZSPIRE is 210 mg administered subcutaneously once every 4 weeks.'
Important Omissions
No label-based discussion of what TEZSPIRE is indicated for (as add-on maintenance for severe asthma; add-on maintenance for CRSwNP in patients aged 12+), nor limitations of use (not for acute bronchospasm/status asthmaticus).
Importance:
Moderate
No label-based counseling/safety omissions were made by the AI response because the response did not address safety at all; however, for any clinical use context, the labeling warns against treating acute asthma symptoms and includes hypersensitivity/other precautions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response is primarily about pricing/cost estimation and does not provide direct medical instructions for clinical management. The only dosing-related issue is mentioning 'every 8 weeks,' which is not supported by the provided label excerpt, but the statement is framed for cost estimation rather than prescribing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple statements about pricing, billing, and out-of-pocket cost are not supported by the provided FDA prescribing information excerpts; additionally, 'every 8 weeks' dosing frequency is not supported by the provided dosing excerpt.
Suggested Improvement
Limit claims to what is supported by the provided prescribing information (e.g., fixed dose 210 mg subcutaneous once every 4 weeks). Remove or clearly label pricing/billing/out-of-pocket workflow statements as non-label information not derivable from the prescribing information excerpts.